A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer

Cancer patients are highly variable in their body composition, specifically in the proportion of fat and muscle. Some patients tend to gain fat and lose muscle (or lean body mass) at the same time. These patients can develop severe muscle wasting, termed sarcopenia. Patients with sarcopenia have more severe treatment related toxicity requiring delays, dose reductions and stopping of treatment, and have reduced survival. One potential explanation for this is that patients with sarcopenia have a reduced volume of lean body mass into which chemotherapy drugs are distributed, resulting in a higher concentration and greater toxicity. This study will randomize lung cancer patients to either the standard dosing strategy based on body surface area or experimental, personalized dosing based on lean body mass. Based on retrospective findings in this patient population, the investigators expect to find that severe toxicity will be reduced for sarcopenic patients on the personalized dosing arm based on lean body mass.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* Recommendation from treating oncologist to receive a cisplatin based chemotherapy regimen, specifically either cisplatin/vinorelbine or cisplatin/gemcitabine
* \> or = 18 years of age
* Histologically proven diagnosis of non-small cell lung cancer, Stage IIIB or IV
* Adequate renal function: creatinine \< 1.5 mg/dL or \< 132 µmol/L and creatinine clearance of \> 45 mL/min using the Cockcroft-Gault formula
* Adequate hepatic function: bilirubin \< 1.5 mg/dL or \< 25 µmol/L and AST and ALT \< 2 times upper limit of normal, unless there is evidence of liver metastases, in which case \< 5 times upper limit of normal
* Adequate hematological function: absolute neutrophil count (ANC) \> 1.5 x 109/L and platelets \> 100 x 109/L and hemoglobin \> 100 g/L
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
* Negative serum pregnancy test for women of childbearing potential. Women and men of child bearing potential must use effective contraception defined as the simultaneous use of two reliable methods unless abstinence is the chosen method.
* Life expectancy of \> 4 months in the opinion of the treating oncologist
* Prior radiotherapy is allowed (unless \> 25% of bone marrow stores) if this radiation was \> 4 weeks before study entry and patient has fully recovered from toxicity of this treatment
* Willingness to comply with the study protocol
* Ability to give written informed consent with the understanding that it may be withdrawn at any time without prejudice

Exclusion Criteria:

* Pregnant or lactating women
* Brain metastases (a CT or MRI is not required to rule out brain metastases unless there is clinical suspicion)
* Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix, in situ ductal breast cancer, non-melanoma skin cancer or low grade bladder cancer
* Patients who have had major surgery within three weeks of enrollment without a full recovery
* Prior treatment with any anticancer therapy
* Patients who have tested positive for HIV
* Any significant medical or psychiatric condition that, in the opinion of the investigator, will exclude the patient from the study for compliance or safety reasons

• BACKGROUNDPrado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008 Jul;9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0. Epub 2008 Jun 6. PMID 18539529
• BACKGROUNDTan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009 Nov 15;15(22):6973-9. doi: 10.1158/1078-0432.CCR-09-1525. Epub 2009 Nov 3. PMID 19887488
• BACKGROUNDPrado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007 Jun 1;13(11):3264-8. doi: 10.1158/1078-0432.CCR-06-3067. PMID 17545532
• BACKGROUNDPrado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009 Apr 15;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242. Epub 2009 Apr 7. PMID 19351764
• BACKGROUNDAntoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19. PMID 20085939